anifrolumab
anifrolumab: 16 clinical trials tracked.
anifrolumab evidence translation
What we can confirm
16 tracked trials
What it means
What to watch
Prepared research question
What is verified about anifrolumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (16)showing 10 most recent
A Non-Interventional Descriptive Multi-Country Study of Saphnelo™ (Anifrolumab-fnia) Utilization in Females of Reproductive Potential
Primary endpoint: Incidence of anifrolumab use
Multicentre, Open-Label, Single-Arm, 52-Week, Ph3b Study to Evaluate the Efficacy and Safety Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Moderate-Severe Systemic Lupus Erythematosus (SLE)
Primary endpoint: The proportion of patients who achieve DORIS remission at week 52
ROSY-S: Rollover Study for Participants Who Have Completed a Previous Study With Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment
Primary endpoint: SAEs and Non-Serious AEs
A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients With Primary Antiphospholipid Syndrome (APS). The AnifAPS Trial
Primary endpoint: Safety and tolerability of anifrolumab
Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)
Primary endpoint: Attainment of DORIS remission
A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab
Primary endpoint: Malignancies
PRIMULA Lac (Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users): The AstraZeneca Lactation Study for Anifrolumab
Primary endpoint: Area under the milk concentration-time curve during a dosing interval
DAHLIA: Achievement of Low Level of Disease Activity With a Dose of Corticosteroids Less Than or Equal to 5 mg (LLDAS5): a Real-life Study With Anifrolumab on Patients With Systemic Lupus Erythematosus in Italy
Primary endpoint: Number and percentage of patients achieving LLDAS5
Pregnancy and Infant Outcomes in Anifrolumab Exposed Pregnancies Using PRegnancy Outcomes Intensive Monitoring (PRIM) Data: The Anifrolumab PRIM Program
Primary endpoint: Major congenital malfunctions
PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users): The AstraZeneca Pregnancy Study for Anifrolumab
Primary endpoint: Composite outcome of all major congenital malformations (MCMs)